Leena Adamian1, Ivan Urits2, Vwaire Orhurhu3, Dylan Hoyt1, Rebecca Driessen1, John A Freeman4, Alan D Kaye5, Rachel J Kaye5, Andrew J Garcia5, Elyse M Cornett6, Omar Viswanath7,8,9. 1. Creighton University School of Medicine, Omaha, NE, USA. 2. Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. iurits@bidmc.harvard.edu. 3. Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. 4. Department of Anesthesiology, Mayo Clinic, Phoenix, AZ, USA. 5. Department of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University School of Medicine, Shreveport, LA, USA. 6. Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. 7. Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE, USA. 8. Valley Anesthesiology and Pain Consultants-Envision Physician Services, Phoenix, AZ, USA. 9. Department of Anesthesiology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
Abstract
PURPOSE OF REVIEW: Urologic chronic pelvic pain syndrome (UCPPS) is a chronic, noncyclic pain condition which can lead to significant patient morbidity and disability. It is defined by pain in the pelvic region, lasting for greater than 3 to 6 months, with no readily identifiable disease process. The aim of this review is to provide a comprehensive update of diagnosis and treatment of UCPPS. RECENT FINDINGS: UCPPS encompasses chronic pelvic pain syndrome or chronic prostatitis (CP/CPPS) in men and interstitial cystitis or painful bladder syndrome (IC/PBS) in women. Underlying inflammatory, immunologic, and neuropathic components have been implicated in the pathogenesis of UCPPS. For optimal patient management, an individualized and multimodal approach is recommended. Medical management and physical therapy are the mainstays of treatment. Injection therapy may offer additional relief in medically refractory patients. Further minimally invasive management may include spinal cord and peripheral nerve stimulation, though evidence supporting efficacy is limited.
PURPOSE OF REVIEW: Urologic chronic pelvic pain syndrome (UCPPS) is a chronic, noncyclic pain condition which can lead to significant patient morbidity and disability. It is defined by pain in the pelvic region, lasting for greater than 3 to 6 months, with no readily identifiable disease process. The aim of this review is to provide a comprehensive update of diagnosis and treatment of UCPPS. RECENT FINDINGS: UCPPS encompasses chronic pelvic pain syndrome or chronic prostatitis (CP/CPPS) in men and interstitial cystitis or painful bladder syndrome (IC/PBS) in women. Underlying inflammatory, immunologic, and neuropathic components have been implicated in the pathogenesis of UCPPS. For optimal patient management, an individualized and multimodal approach is recommended. Medical management and physical therapy are the mainstays of treatment. Injection therapy may offer additional relief in medically refractory patients. Further minimally invasive management may include spinal cord and peripheral nerve stimulation, though evidence supporting efficacy is limited.
Authors: Alicia María de Pedro Negri; María Jesús Ruiz Prieto; Esther Díaz-Mohedo; Rocío Martín-Valero Journal: Int J Environ Res Public Health Date: 2022-05-10 Impact factor: 4.614
Authors: Ivan Urits; Ruben Schwartz; Harish Bangalore Siddaiah; Sathyadev Kikkeri; David Chernobylsky; Karina Charipova; Jai Won Jung; Farnad Imani; Mohsen Khorramian; Giustino Varrassi; Elyse M Cornett; Alan David Kaye; Omar Viswanath Journal: Anesth Pain Med Date: 2021-02-16